Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial

Papillary renal-cell carcinoma type 1 (PRCC1) is associated with MET gene alterations. Our phase II trial prospectively assessed the efficacy and safety of crizotinib in patients with advanced/metastatic PRCC1 with or without MET mutations (MET+ and MET-).

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European Journal of Cancer 2017-12, Vol.87, p.147-163
Hauptverfasser: Schöffski, Patrick, Wozniak, Agnieszka, Escudier, Bernard, Rutkowski, Piotr, Anthoney, Alan, Bauer, Sebastian, Sufliarsky, Jozef, van Herpen, Carla, Lindner, Lars H, Grünwald, Viktor, Zakotnik, Branko, Lerut, Evelyne, Debiec-Rychter, Maria, Marréaud, Sandrine, Lia, Michela, Raveloarivahy, Tiana, Collette, Sandra, Albiges, Laurence
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Papillary renal-cell carcinoma type 1 (PRCC1) is associated with MET gene alterations. Our phase II trial prospectively assessed the efficacy and safety of crizotinib in patients with advanced/metastatic PRCC1 with or without MET mutations (MET+ and MET-).
ISSN:0959-8049